DE602004019812D1 - Marker für neuromyelitis optica - Google Patents

Marker für neuromyelitis optica

Info

Publication number
DE602004019812D1
DE602004019812D1 DE602004019812T DE602004019812T DE602004019812D1 DE 602004019812 D1 DE602004019812 D1 DE 602004019812D1 DE 602004019812 T DE602004019812 T DE 602004019812T DE 602004019812 T DE602004019812 T DE 602004019812T DE 602004019812 D1 DE602004019812 D1 DE 602004019812D1
Authority
DE
Germany
Prior art keywords
markers
neuromyelitis optica
optica
neuromyelitis
nmo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004019812T
Other languages
English (en)
Inventor
Vanda A Lennon
Thomas J Kryzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of DE602004019812D1 publication Critical patent/DE602004019812D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
DE602004019812T 2003-11-25 2004-11-24 Marker für neuromyelitis optica Active DE602004019812D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/723,180 US7101679B2 (en) 2003-11-25 2003-11-25 Marker for neuromyelitis optica
PCT/US2004/039710 WO2005051178A2 (en) 2003-11-25 2004-11-24 Marker for neuromyelitis optica

Publications (1)

Publication Number Publication Date
DE602004019812D1 true DE602004019812D1 (de) 2009-04-16

Family

ID=34592190

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019812T Active DE602004019812D1 (de) 2003-11-25 2004-11-24 Marker für neuromyelitis optica

Country Status (9)

Country Link
US (5) US7101679B2 (de)
EP (1) EP1700120B1 (de)
JP (1) JP4538464B2 (de)
CN (1) CN1910456B (de)
AT (1) ATE424560T1 (de)
DE (1) DE602004019812D1 (de)
ES (1) ES2320006T3 (de)
IN (1) IN2014DN05011A (de)
WO (1) WO2005051178A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica
US20070093673A1 (en) * 2005-10-24 2007-04-26 Andre Vachereau Boron-containing compounds, uses and preparation thereof
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン4阻害薬
WO2009039363A2 (en) * 2007-09-20 2009-03-26 Mayo Foundation For Medical Education And Research Neuromyelitis optica autoantibodies as a marker for neoplasia
JP5117336B2 (ja) * 2008-09-18 2013-01-16 国立大学法人 千葉大学 多発性硬化症またはnmoの検査マーカーの測定方法
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
GR1007341B (el) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Διαγνωστικος προσδιορισμος
EP2569630A4 (de) 2010-05-13 2013-10-30 Univ New Jersey Med Diagnostische autoantikörper-profile zur erkennung und diagnose neurodegenerativer erkrankungen
DE102011011280A1 (de) 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
EP2699256B1 (de) * 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Zusammensetzungen und verfahren zur behandlung von neuromyelitis optica
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
CN104040344A (zh) * 2011-10-21 2014-09-10 德克萨斯系统大学评议委员会 视神经脊髓炎的密码子标签
JP6265119B2 (ja) * 2012-03-30 2018-01-24 コニカミノルタ株式会社 生体物質検出方法
WO2013177116A1 (en) * 2012-05-21 2013-11-28 The Regents Of The University Of California Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica
CN102898513B (zh) * 2012-10-31 2016-03-16 徐俊 ELISpot视神经脊髓炎诊断试剂盒及其应用
EP2979094B1 (de) 2013-03-28 2018-08-29 Protagen AG Verfahren zur diagnose von neuromyelitis optica
US20170080063A1 (en) * 2014-05-19 2017-03-23 The Johns Hopkins University Highly soluble aquaporin-4 extracellular loop c peptide immunization for treatment of neuromyelitis optica
US20170130269A1 (en) * 2014-06-30 2017-05-11 Siemens Healthcare Gmbh Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers
CN104698190A (zh) * 2015-03-16 2015-06-10 中国人民解放军总医院 用于中枢神经系统脱髓鞘疾病的生物诊断标记物
US10098935B2 (en) * 2015-05-01 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Aquaporin tolerizing vaccines and methods of use thereof
WO2017197293A1 (en) * 2016-05-13 2017-11-16 C.R. Bard, Inc. Peripherally inserted central catheter systems, devices, and methods thereof for pediatrics
CN106318974A (zh) * 2016-08-29 2017-01-11 南方医科大学南方医院 细胞固定工艺及通过该工艺制备aqp4抗体检测试剂盒
KR101977843B1 (ko) 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
JP7067800B2 (ja) * 2017-04-12 2022-05-16 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
KR102089042B1 (ko) * 2017-05-16 2020-03-13 서울대학교병원 보체불활성화법을 이용한 항-아쿠아포린 4 항체의 개선된 검출 방법
CN108998450A (zh) * 2018-08-08 2018-12-14 昆明医科大学第附属医院 引物、cDNA、载体、AQP4单克隆抗体及制备方法
CN110618264A (zh) * 2019-09-10 2019-12-27 南方医科大学 基于量子点聚苯乙烯微球检测抗aqp4抗体的方法
CN111272998A (zh) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
CN115232795B (zh) * 2021-07-22 2023-09-19 北京和合医学诊断技术股份有限公司 稳定表达aqp4-m23蛋白的细胞株及其构建方法、应用
CN113358881B (zh) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 用于nmosd预测或复发监测的生物标志物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37273A (en) * 1863-01-06 Improved canteen
US4708713A (en) * 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5214136A (en) * 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
DE4227695C1 (de) * 1992-08-21 1993-10-07 Fresenius Ag Zentrifuge zum Auftrennen von Blut in seine Bestandteile
US5676644A (en) 1995-06-07 1997-10-14 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
AU1059897A (en) * 1995-11-09 1997-05-29 Trustees Of Boston University Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector
EP1147011A1 (de) 1998-11-25 2001-10-24 Amarillo Biosciences, Inc. Durch alpha-interferon vermittelte steigerung der aquaporin expression
US20040014087A1 (en) 1999-06-01 2004-01-22 Incyte Corporation Molecules for diagnostics and therapeutics
US6409726B1 (en) * 1999-11-08 2002-06-25 Alan G. Ellman Electrosurgical instrument for ear surgery
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040048253A1 (en) 2001-02-21 2004-03-11 Panzer Scott R. Molecules for diagnostics and therapeutics
US7251568B2 (en) 2001-04-18 2007-07-31 Wyeth Methods and compositions for regulating bone and cartilage formation
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
DE50304634D1 (de) * 2002-06-22 2006-09-28 Spinner Gmbh Elektrotech Koaxialer Steckverbinder
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica

Also Published As

Publication number Publication date
EP1700120A4 (de) 2007-11-14
WO2005051178A2 (en) 2005-06-09
US8524508B2 (en) 2013-09-03
WO2005051178A3 (en) 2005-12-29
EP1700120A2 (de) 2006-09-13
US7101679B2 (en) 2006-09-05
US20120219969A1 (en) 2012-08-30
ES2320006T3 (es) 2009-05-18
IN2014DN05011A (de) 2015-07-10
JP2007518068A (ja) 2007-07-05
US7947254B2 (en) 2011-05-24
ATE424560T1 (de) 2009-03-15
CN1910456B (zh) 2011-04-13
US20050112116A1 (en) 2005-05-26
JP4538464B2 (ja) 2010-09-08
US20140314796A1 (en) 2014-10-23
US20080145870A1 (en) 2008-06-19
US20090143710A1 (en) 2009-06-04
EP1700120B1 (de) 2009-03-04
CN1910456A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
DE602004019812D1 (de) Marker für neuromyelitis optica
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
HK1092841A1 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DE60127104D1 (de) Prostatakrebs-marker
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
ECSP045466A (es) Inhibidores de la peptido-desformilasa
SE0301650D0 (sv) Novel compounds
ITTO20020117A0 (it) Apparecchiatura per prove tribologiche.
MA28354A1 (fr) Nouvelles combinaisons d'un agent anti-emetique et d'un inhibiteur de l'enkephalinase
DE60219633D1 (de) LÄNGLICHER KANISTER FÜr EINEN AUTOMATISIERTEN MIKROBIOLOGISCHEN ANALYSATOR
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE60326773D1 (de) Peptid-deformylase-hemmer
EA200500878A1 (ru) Кальцилитические соединения
DE60207833D1 (de) Peptiddeformylase-hemmer
ATE548037T1 (de) Peptid-deformylase-hemmer
IS7441A (is) Peptíðdeformýlasatálmar
BRPI0514851A (pt) marcadores de polipeptìdio para o diagnóstico de arteriosclerose
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ATE346915T1 (de) Hybrid topoisomerasen und ihre verwendung
ATE309984T1 (de) Peptid-deformylase-hemmer
WO2004110243A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING THE IDENTIFICATION OF PRION PROTEIN PRPsc

Legal Events

Date Code Title Description
8364 No opposition during term of opposition